The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemia
Priyanka Khare, Ronghua Zhang, Cristina Ivan, Sarah M. Schneider, Priyanka Banerjee, Navid Sobhani, Harry L Polasek, Vanessa Behrana Jensen, Karen Clise-Dwyer, William G. Wierda, Maria Teresa Sabrina Bertilaccio
This paper investigates the antileukemic effects of CD19-4-1BBL in chronic lymphocytic leukemia, showing it mitigates immunosuppression and enhances CD8+ T-cell immunity in preclinical models.
bioRxiv · Jul 15, 2026 · PreprintImmunology